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ABSTRACT
Objective To determine the cost effectiveness of one-off
population based screening for chronic kidney disease
based on estimated glomerular filtration rate.
Design Cost utility analysis of screening with estimated
glomerular filtration rate alone compared with no
screening (with allowance for incidental finding of cases
of chronic kidney disease). Analyses were stratified by
age, diabetes, and the presence or absence of
proteinuria. Scenario and sensitivity analyses, including
probabilistic sensitivity analysis, were performed. Costs
were estimated in all adults and in subgroups defined by
age, diabetes, and hypertension.
Setting Publicly funded Canadian healthcare system.
Participants Large population based laboratory cohort
usedtoestimatemortalityratesandincidenceofendstage
renaldiseaseforpatientswithchronickidneydiseaseover
a five year follow-up period. Patients had not previously
undergone assessment of glomerular filtration rate.
Main outcome measures Lifetime costs, end stage renal
disease, quality adjusted life years (QALYs) gained, and
incremental cost per QALY gained.
Results Compared with no screening, population based
screening for chronic kidney disease was associated with
an incremental cost of $C463 (Canadian dollars in 2009;
equivalent to about £275, €308, US $382) and a gain of
0.0044 QALYs per patient overall, representing a cost per
QALYgainedof$C104900.Inacohortof100000people,
screening for chronic kidney disease would be expected
to reduce the number of people who develop end stage
renal disease over their lifetime from 675 to 657. In
subgroups of people with and without diabetes, the cost
per QALY gained was $C22600 and $C572000,
respectively.In acohortof100000peoplewithdiabetes,
screening would be expected to reduce the number of
people who develop end stage renal disease over their
lifetime from 1796 to 1741. In people without diabetes
with and without hypertension, the cost per QALY gained
was $C334000 and $C1411100, respectively.
Conclusions Population based screening for chronic
kidney disease with assessment of estimated glomerular
filtration rate is not cost effective overall or in subgroups
of people with hypertension or older people. Targeted
screening of people with diabetes is associated with a
cost per QALY that is similar to that accepted in other
interventions funded by public healthcare systems.
INTRODUCTION
End stage renal disease and its precursor chronic kid-
ney disease are emerging public health problems
because of their associated adverse clinical outcomes,
poor quality of life, and high healthcare costs. Given
that chronic kidney disease (defined as glomerular fil-
tration rate below 60 ml/min/1.73 m
2) is often not
detected until it is advanced, screening programmes
using blood or urine tests have been recommended.
1-3
With population based screening, however, there are
potentialbenefits(suchasearlyidentificationandtreat-
mentofaffectedpatients)anddrawbacks(suchasiden-
tification of patients with only mild disease, in whom
additional treatment might not be warranted).
4
Several studies have examined the effectiveness of
screening for chronic kidney disease with estimated
glomerular filtration rate or urinalysis.
5-9 Previous stu-
dies of screening in high risk groups have found that it
would identify one person with disease for every three
to six people screened,
5-10 whereas population based
screening would detect one for every 16-21 people
screened.
1011 Existing cost effectiveness studies have
examined screening only with urinalysis.
1213 As only
26% and 3% of North Americans with glomerular fil-
tration rate <30 ml/min/1.73 m
2, and 30-60 ml/min/
1.73 m
2, respectively, have macroalbuminuria on uri-
nalysis, this form of screening would be expected to
miss a considerable proportion of people with chronic
kidney disease.
10
Whileclinicalpracticeguidelinesforchronickidney
diseasefrom the National KidneyFoundation/Kidney
Dialysis Outcomes Quality Initiative have recom-
mended targeted screening of high risk patients,
including those with diabetes or hypertension and
aged>60,
114othershavesuggestedapopulationbased
approach.
41516TheInternationalFederationofKidney
Foundations recently surveyed its 28 member nations
on the existence of screening programmes for chronic
kidney disease, and 24 reported some form of screen-
ing activity.
17 While most programmes entailed
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BMJ | ONLINE FIRST | bmj.com page 1 of 12screening for disease among high risk groups, includ-
ingthosewithhypertension,diabetes,andafamilyhis-
tory of chronic kidney disease and older people, a few
countries, including Hong Kong, Japan, and the Neth-
erlands, have active population based screening pro-
grammes. Given the current interest in screening, as
well as the controversy concerning its optimal use, we
assessed the cost effectiveness of population based
screening for chronic kidney disease based on esti-
mated glomerular filtration rate alone (compared
with no screening) in all adults and in subgroups of
people defined by age, diabetes, and hypertension.
METHODS
Overview and validation
We carried out an incremental cost utility analysis of
one-off screening for chronic kidney disease with esti-
mated glomerular filtration rate compared with no
screeninginadultswithnopreviousassessment ofglo-
merular filtration rate. The box shows a high level
overview of the modelling process.
In the base case analysis we used the perspective of
the publiclyfundedhealthcaresystem.Healthbenefits
were measured in cases of end stage renal disease pre-
vented and quality adjusted life years (QALYs) gained
over a lifetime. We also assessed the incremental cost
associated with screening for chronic kidney disease
and measured the incremental cost per QALY gained.
Costsandbenefitswerediscountedat5%annually.All
costs were inflated to 2009 Canadian dollars (1 $C=
£0.59=€0.67=US$0.83)by usingthe Canadianhealth-
care consumer price index.
Computer simulation model
WeconstructedaMarkovmodelusingdecisionanaly-
sis software (TreeAge Pro Suite 2007, Williamstown,
MA) in accordance with existing guidelines for eco-
nomic evaluation.
19 Base case analyses were per-
formed with Markov cohort simulation with
transitions modelled on an annual basis, though we
used first order Monte Carlo simulation to determine
the incidence of end stage renal disease over time. We
considered several health states in both the screening
and no screening strategies, including people without
chronickidneydisease,thosewithnon-dialysischronic
kidneydisease,patientsreceivingdialysis,andpatients
with a functioning transplant.
Model validity was established,
20 including internal
validation with primary clinical data (R
2 between
model outcomes and primary data was >0.97 for
both end stage renal disease and mortality at five
years) and external validity by comparing with other
published reports.
2122 Among patients with chronic
kidney disease, mortality and end stage renal disease
was 24% and 2.7% at five years and 71% and 4.1% at
20 years, respectively. Several models were evaluated,
and,giventheexcellentperformanceofallmodels,we
used the simplest and most transparent model, where
chronic kidney disease is represented as one health
state (as opposed to modelling patients with varying
severityofchronickidneydiseaseasthreeseparatedis-
ease states
1), in accordance with optimal modelling
guidelines.
20 Additional benefits of modelling with
onlyonehealthstateisthatitoffersincreasedflexibility
to incorporate estimates of benefit (that is, relative risk
for end stage renal disease and death) as reported in
clinical trials, compared with models that use several
distinct stages of chronic kidney disease based on
severity of disease.
Data inputs
We based the prevalence of non-dialysis chronic kid-
ney disease (estimated glomerular filtration rate
<60 ml/min/1.73 m
2) on the results of the National
HealthandNutritionExaminationSurveyIII,arepre-
sentative survey of the North American population
stratified by age and the presence of diabetes.
10 In the
survey, conducted by the National Center for Health
StatisticsintheUnitedStates,data(includingestimated
Overview of analysis
 The prevalence of undiagnosed chronic kidney disease in different subgroups of
patients stratified by age (<65 or ≥65) and diabetes was determined from a North
American population based survey
10
 The natural course of chronic kidney disease was then determined within the Alberta
Kidney Disease Network,
18 a large population based laboratory cohort of patients, with
mortality rates and incidence of end stage renal disease estimated over a five year
follow-up period
 Screening for chronic kidney disease would be expected to identify patients with no
previous diagnosis who could then receive angiotensin blockade
 The relative risks of end stage renal disease and death associated with angiotensin
blockade were taken from high quality published meta-analyses
 This information was combined with decision analysis to examine the long term
outcomes and costs for a strategy of screening for chronic kidney disease and
subsequent management of patients compared with no screening (disease
undiagnosed and untreated until detected incidentally during routine care)
Table 1 |Baseline characteristics of patient cohort from Alberta Kidney Disease Network.
Figures are numbers (percentages) of patients unless otherwise specified
Overall
(n=290 613)
Peoplewithdiabetes
(n=30 277)
People without
diabetes (n=260 336)
Mean (SD) age (years) 55 (18) 64 (14) 54 (18)
Aged ≥65 90 090 (31) 15 139 (50) 75 497 (29)
Women 168 555 (58) 14 533 (48) 153 598 (59)
CKD (estimated GFR in ml/min/1.73 m
2):
None (≥60) 235 160 (81) 19 788 (65) 215 372 (83)
Stage 3 (30-59.9) 51 591 (18) 9162 (30) 42 429 (16)
Stage 4 (15-29.9) 2962 (1) 1000 (3) 1962 (1)
Stage 5 (<15) 900 (0) 327 (1) 573 (0)
Determination of proteinuria* 12754/55 453 (23) 9021/10 489 (86) 7644/44 964 (17)
Presence of proteinuria*† 893/12 754 (7) 812/9021 (9) 459/7644 (6)
Comorbidity (%)*:
Myocardial infarction 4658/55 453 (8) 1704/10 489 (16) 2954/44 964 (7)
Peripheral vascular disease 2462/55 453 (4) 909/10 489 (9) 1553/44 964 (3)
Cerebrovascular disease 3295/55 453 (6) 1035/10 489 (10) 2260/44 964 (5)
Median(IQR)Charlsoncomorbidityscore* 0 (0-1) 1 (0-3) 0 (0-0)
CKD=chronic kidney disease; GFR=glomerular filtration rate; IQR=interquartile range.
*Patients with CKD stage 3-5 only
†Among people with CKD (GFR <60 ml/min/1.73 m
2), proteinuria defined as present if urine dipstick was > trace
or urine protein:creatinine ratio >23 mg/mmol (>200 mg/g).
19
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methods according to standardised protocols.
23
We also used data from the Alberta Kidney Disease
Network,
18arepositoryoflaboratorydataforroutinely
collected tests (including estimated glomerular filtra-
tion rate) for the entire province of Alberta, Canada.
Patients in the laboratory repository are linked to pro-
vincial healthcare programmes, which care for all
dialysis and transplant patients,
24 and to provincial
administrativedata(usingtheuniqueprovincialhealth
number) to obtain demographic information (includ-
ing death) and details regarding use of healthcare
resources (physician claims, admission to hospital,
and use of prescription drugs (for people aged ≥65)).
18
Data from the network enabled us to estimate the
annual incidence of end stage renal disease and death
inacohortofAlbertansreceivingroutinecarebetween
May 2002 and December 2007 (table 1). The initial
and subsequent glomerular filtration rate for these
patients was estimated with an equation from the
Four Variable Modification of Diet in Renal Disease
Study,
25 with the baseline rate being defined by the
mean estimated rate of all measurements during the
first year. Diabetes mellitus was identified from hospi-
tal discharge records and physicians’ claims,
26 and
other chronic medical conditions were identified with
validated algorithms.
2728 Proteinuria was defined as
more than trace on a urine dipstick or if the urine pro-
tein:creatinineratiowas>23mg/mmol(>200mg/g).
18
The cohort included 290613 individuals, of whom
55453 had chronic kidney disease and30277 had dia-
betes. All participants were followed to ascertain the
incidence of death, end stage renal disease, and renal
replacementtherapy until 31 December 2007. Annual
rates of these outcomes (stratified by age, presence of
diabetes and presence of proteinuria) were estimated
foruptofiveyearsaftertheindexmeasurementofglo-
merular filtration rate, with censoring at end stage
renal disease, death, or 31 December 2007 (table 2
and table 3).
Mortality
Forpeoplewithoutchronickidneydisease,agedepen-
dent population mortality rates were estimated from
observed rates for Canadians.
29 For people with
chronic kidney disease, mortality rates were based on
the annual rate observed within the Alberta Kidney
Table 2 |Annual probability of end stage renal disease and mortality in people with chronic
kidney disease in Alberta Kidney Disease Patient cohort, stratified by diabetes and presence
of proteinuria*
Variables
Without diabetes (n=44 964) With diabetes (n=10 489)
No proteinuria Proteinuria No proteinuria Proteinuria
End stage renal disease
Age <65:
Year 1 0.0037 0.0523 0.0049 0.0547
Year 2 0.0024 0.0380 0.0013 0.0608
Year 3 0.0011 0.0336 0.0045 0.0630
Year 4 0.0031 0.0296 0.0053 0.0703
Year 5 0.0014 0.0340 0.0083 0.0597
Age ≥65:
Year 1 0.0011 0.0274 0.0029 0.0377
Year 2 0.0015 0.0243 0.0015 0.0340
Year 3 0.0008 0.0158 0.0027 0.0193
Year 4 0.0022 0.0235 0.0023 0.0232
Year 5 0.0015 0.0255 0.0018 0.0306
Mortality
Age <65:
Year 1 0.0024 0.0182 0.0122 0.0369
Year 2 0.0054 0.0299 0.0186 0.0478
Year 3 0.0116 0.0222 0.0240 0.0243
Year 4 0.0115 0.0288 0.0234 0.0690
Year 5 0.0136 0.0194 0.0361 0.0409
Year 6-10† 0.008 0.028 0.0258 0.0559
Year 11-15† 0.012 0.045 0.0252 0.0523
Year 16-20† 0.015 0.044 0.0321 0.0550
Year 21-25† 0.019 0.053 0.0405 0.0632
Year 26-30† 0.027 0.069 0.0465 0.0954
Year 31-35† 0.032 0.053 0.0591 0.0912
Year 36-40† 0.053 0.093 0.0742 0.1249
Year 41-45† 0.066 0.131 0.0993 0.0999
Year 45-50† 0.052 0.135 0.1459 0.1973
Age ≥65:
Year 1 0.0124 0.0570 0.0258 0.0640
Year 2 0.0208 0.0759 0.0483 0.0883
Year 3 0.0288 0.0842 0.0528 0.0889
Year 4 0.0363 0.0907 0.0613 0.1019
Year 5 0.0438 0.0962 0.0638 0.0937
Year 6-10† 0.030 0.079 0.0545 0.0841
Year 11-15† 0.042 0.110 0.0646 0.1237
Year 16-20† 0.061 0.165 0.0940 0.1165
Year 21-25† 0.079 0.129 0.1095 0.1559
*Incidence of proteinuria at age <65 was 0.20 in those without diabetes and 0.32 in those with diabetes and
0.16 and 0.22, respectively, at age ≥65.
10
†Based on probability of mortality observed in progressively older patients. For example, mean age of patients
<65 was 55, and mortality over first five years for this cohort is reported per year by using full cohort. Mortality
for years 6-10 estimated on mortality observed for patients with mean age 60 (range 57-63) within each of four
diabetes/proteinuria subgroups, while mortality for years 11-15 was based on mortality observed for patients
with mean age 65 (63-68) within each of four diabetes/proteinuria subgroups.
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Fig 1 | Impact of screening for chronic kidney disease in cohort
of 100000 people on number of cases of end stage renal
disease overall and for people with and without diabetes
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estimated glomerular filtration rate. We accounted for
agerelatedincreasesin mortality inthose withchronic
kidney disease based on the observed mortality rates
for patients in different age groups in the network
(table 2 and table 3).
Adherence with screening and incidental case finding
Weassumedthat50%ofpeoplewouldagreetoscreen-
ing, which requires venipuncture.
30 As estimation of
glomerularfiltrationratecanalsooccurduringroutine
care, irrespective of screening, we assumed that a pro-
portion of unscreened people would undergo such
assessment each year. Using data from the network
(to determine the number of people undergoing their
first creatinine measurements each year) and the 2006
Canadian census (to define the total Alberta
population
31), we estimated the annual likelihood of
undergoing incidental screening for chronic kidney
disease in this previously unscreened population.
Diagnostic investigation for people in whom screening
identified chronic kidney disease
We assumed that all people with newly diagnosed
chronic kidney disease would undergo evaluation by
a nephrologist, including a standard laboratory inves-
tigation (table 4). This assumption was tested in a sen-
sitivity analysis,inwhich we assumedthatonly 20% of
patients were assessed by a nephrologist with the
remaindermanagedbyaprimarycarephysician.Con-
sistent withprevioussurveysof physicians,
1232 we also
assumedthatakidneybiopsywouldbedonein5%and
20% of people with incident chronic kidney disease
with and without diabetes.
Effectiveness of angiotensin blockade for people with
chronic kidney disease
The benefit of screening for chronic kidney disease is
assumed to be the detection of previously undiagnosed
disease, enabling appropriate assessment and manage-
ment.Whiledetectionofpreviouslyundiagnoseddisease
or undiagnosed severe glomerulonephritis requiring
immunosuppression is possible, nearly all people
detectedbyscreeningwouldhavestage3chronickidney
disease unrelated to glomerulonephritis
10; as such, man-
agement would focus on control of blood pressure
through the use of angiotensin blockade, particularly in
people with proteinuria.
33-35 While it is possible that peo-
ple with chronic kidney disease identified by screening
would already be receiving angiotensin blockade, given
that the target population consisted of people in whom
glomerular filtration rate had not previously been mea-
sured, we assumed that this would not be the case.
We assumed that people found to have chronic kid-
ney disease would receive an ACE (angiotensin con-
verting enzyme) inhibitor or angiotensin blocker (if
tolerated), with a target blood pressure of <130/
80 mm Hg. We based the effectiveness of angiotensin
blockadebyconductingafocusedliteraturesearchthat
identifiedrelevanthighquality meta-analysesand ran-
domised trials in people with chronic kidney
disease.
3335-42Astheeffectivenessofangiotensinblock-
adeatreducingendstagerenaldiseaseanddeathvaries
by diabetes and proteinuria status, we estimated the
relative risk for these outcomes separately in these
four subgroups (table 4).
Table 3 |Annual probabilities of events in people with end
stage renal disease
Variables Probability
Annual mortality on dialysis (95% CI)
Age <65 0.077 (0.072 to 0.083)
43
Age ≥65 0.212 (0.202 to 0.223)
43
Annual mortality for patients with functioning transplant*
Age <65:
Year 1 0.012
Year 2 0.007
Year 3 0.001
Year 4 0.007
Year 5 0.003
Age ≥65:
Year 1 0.071
Year 2 0.051
Year 3 0.054
Year 4 0.043
Year 5 0.030
Initial probability of treatment being dialysis (rather than transplant)
after developing end stage renal disease*
Age <65 0.854
Age ≥65 0.989
Subsequent annual probability of transplant for dialysis patients*
Age <65 0.108
Age ≥65 0.008
Annualprobabilityoftransplantfailurerequiringreturntodialysis(95%
CI)
All 0.04 (0 to 0.1)
62
*From Alberta Kidney Disease Network cohort.
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Fig 2 | Incremental cost effectiveness of population based screening for chronic kidney disease
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For people without chronic kidney disease, screening
includedavisittoaprimarycarephysicianandmeasure-
mentofglomerularfiltrationrate,atacostofabout$C48
(table 5). In patients found to have chronic kidney dis-
ease, the cost of screening was about $C83, accounting
for an additional follow-up visit to a physician.
Costs related to managing chronic kidney disease with and
without dialysis
The cost of managing people with chronic kidney dis-
ease was assumed to be the incremental costs resulting
from a new diagnosis, including those of nephrologist
care, the requirement for angiotensin blockade, and
laboratory monitoring (table 5). As admission to hos-
pitalinpatientswithstage3-5non-dialysischronickid-
ney disease is usually because of comorbidity and
because randomised trials of management of chronic
kidney disease have not shown that interventions pre-
vent admissions, we did not include the cost of admis-
sions in our analysis. The annual cost of dialysis was
estimated at $C64218, assuming that nearly 81% of
people were treated in haemodialysis centres.
4344 The
cost of transplantation was estimated at $C84531 for
year one and $C35545 for subsequent years.
45
Valuing health benefits
Health benefits were measured in cases of end stage
renal disease prevented and QALYs gained. We did
notassumeanydifferenceinutilityestimatesfor“diag-
nosed” and “undiagnosed” chronic kidney disease, as
studies of antihypertensive therapy (the only addi-
tional treatment in people with diagnosed chronic kid-
neydisease)suggestnosignificantimpactonqualityof
life.
46 We estimated utilities for relevant health states
(dialysis and transplantation) based on contemporary
Canadian studies.
4547
Sensitivity and scenario analyses
Sensitivity and scenario analyses were performed to
determine the impact of uncertainty on the results of
themodelbyvaryingallkeyparametersthroughplau-
sibleranges.Weconductedanadditionalscenarioana-
lysis examining the cost effectiveness of screening in
Table 4 |Additional clinical information required for base case analysis. Data shown with 95% confidence intervals when
available
Variables
Mean base case estimate
overall (95% CI)
Base case estimate in people with CKD
Without diabetes With diabetes
Proportion of general population aged <65 0.629
31 ——
Proportion of general population with diabetes:
Age <65 0.044
61 ——
Age ≥65 0.183
61 ——
Incidence of CKD in general population:
Age <65 0.035
10 0.075
10
Age ≥65 0.186
10 0.277
10
ProportionofpatientsidentifiedashavingCKDin
whom kidney biopsy is undertaken
— 0.20
32 0.051
Adherent with screening 0.50 (0.25 to 0.75)
30 —
Utility (range 0-1):
People with CKD 0.85 (0.55 to 0.9)
63 ——
Age <65 on dialysis 0.639 (0.45 to 0.7)
47 64 ——
Age ≥65 on dialysis 0.572 (0.55 to 0.8) ——
Patients with functioning transplant 0.816 (0.65 to 0.9)
45 64 ——
Relative risks associated with angiotensin blockade in patients with CKD:
ESRD in people with proteinuria — 0.59 (0.37 to 0.94)*
39 0.64 (0.4 to 1.03)
35
ESRD in people without proteinuria — 1.01 (0.44 to 2.32)
39 1.00 (0.67 to 2.30)
35 37 65
Death in people with proteinuria — 1.00 (0.55 to 2.93)*
38 0.79 (0.63 to 0.99)
35
Death in people without proteinuria — 1.00 (0.36 to 2.17)
38 0.84 (0.75 to 0.95)†
37 65
Annual discount rate:
Costs 0.05 (0 to 0.06)
19 ——
Utilities 0.05 (0 to 0.06)
19 ——
CKD=chronic kidney disease; ESRD=end stage renal disease.
*While Jafar et al
39 and Giatras et al
38 both present data from Angiotensin Converting Enzyme Inhibition and Progressive Renal Disease Study
Group, who analysed patient level data from 10 and 11 randomised trials, respectively, comparing ACE inhibitors in patients without diabetes with
CKD, data from Jafar et al is used for ESRD as it reports data stratified by proteinuria, while data from Giatras et al is used for mortality as they
conducted analyses with and without including study of Maschio et al,
66 a small randomised controlled trial reporting relative risk of mortality of 7.55
(95% CI 0.95 to 60.0) associated with use of ACE inhibitor, which was thought implausible. Data from Giatras et al excluding this trial showed no
significant different in relative risk of mortality associated with use of ACE inhibitors.
†While Strippoli et al
35 presented relative risk of ESRD in patients with diabetes and CKD, most patients had nephropathy and baseline proteinuria.
As such, relative risk of ESRD and mortality for patients with diabetes and proteinuria was estimated from Strippoli et al,
35 while relative risk of ESRD
and mortality for patients with diabetes without proteinuria was estimated from microHOPE study,
37 which excluded patients with overt nephropathy.
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reflecting an increased prevalence of chronic kidney
diseaseinpeople withhypertension,
10aswellasa dou-
bling of the risk of progression to end stage renal dis-
ease among people with hypertension.
48 As the cost of
managing people with chronic kidney disease varies
basedonpracticepatterns,we alsoassessedtheimpact
of using alternative cost estimates on results.
Toaddresslimitationsinclassicunivariatesensitivity
analysis,weperformedMonteCarlosimulation,which
allows for the simultaneous sensitivity analysis of all
variables over their plausible range.
4950 It does so by
replacing estimates of probabilities, utilities, and costs
with specific probability distributions, which are based
onthe reported meansandvariancesforeachvariable.
Statistical distributions were created around all of the
variablesforwhichtherewassubstantialuncertaintyof
measurement, including use of a β distribution for pro-
portions (that is, the risk of end stage renal disease and
mortality), use of a normal distribution for normally
distributed variables (that is, certain costs, relative
risks,andutilitymeasures),andlognormaldistribution
for skewed variables (that is, certain costs).
RESULTS
Baseline analyses
Compared with no screening, population based
screening for chronic kidney disease was associated
with an incremental cost of $C463 and a gain of
0.0044 QALYs per patient overall, representing a
cost per QALY gained of $C104900 (table 6). In a
cohortof100000people,screeningwouldbeexpected
to reduce the number of people developing end stage
renaldiseaseovertheirlifetimefrom675to657(fig1).
In subgroupsof people aged <65 and ≥65, the cost per
QALY gained associated with screening was $C
200100 and $C93700, respectively (table 6).
Table 5 |Average cost of care associated with managing patients with newly diagnosed chronic kidney disease (CKD) Figures
are $C, 2009
Costs with source
Cost estimate by CKD stage* (GFR)
Stage 3
(30-60 ml/min)
Stage 4
(15-30 ml/min)
Stage 5
(<15 ml/min)
Cost of screening (Alberta Schedule of Medical Benefits):
People found to have CKD 83
People without CKD 48
Specialist visits for people found to have CKD (Alberta Schedule of Medical Benefits)†:
Year 1 226 226 302
Years 2 and on 189 189 302
Testing for people with CKD:
Urine studies
44‡:
Year 1 130 130 130
Years 2 and on 109 109 109
Haematology and serology
44§:
Year 1 129 180 326
Years 2 and on 108 158 304
Radiological studies (year 1)
44:
Renal ultrasonography
44 325
Biopsy/pathology (year 1):
Renal biopsy (when indicated)
44¶ 538
Medications for people with known CKD (all years):
ACE inhibitor
67** 378 378 378
Additional anti-hypertensives
67†† 857 857 857
Mean cost of erythropoietin stimulating agent (ESA) for people with known CKD
receiving ESA
68‡‡
2668/patient
Multidisciplinary CKD clinics
69 70§§ 1590/patient
CKD=chronic kidney disease; GFR=glomerular filtration rate.
*Total annual cost of managing patients with CKD (GFR <60 ml/min) based on proportion of patients with CKD stages 3, 4, and 5 (see table 1) and
relative cost of managing patients with stages 3, 4, and 5.
†Assumes that patients with stages 3 and 4 CKD are seen annually, while patients with non-dialysis stage 5 CKD are seen every four months.
‡Assumes that urine protein:creatinine ratio is monitored every 3 months, with urine protein electrophoresis conducted once in year 1 only.
§Assumes that complete blood count, electrolytes, serum phosphate, calcium, and albumin are measured every 3, 2, and 1 months for patients with
stages 3, 4, and 5 CKD, respectively, with serum protein electrophoresis being conducted once in year 1 only.
¶Only 20%, and 5% of people without and with diabetes require biopsy.
12 32
**Assumes that 75%
69 of people are treated with ACE inhibitor (generic ramipril $0.63/day), and 25% with angiotensin blockers (irbesartan $1.21/
day) plus appropriate pharmacist prescribing fees.
††On average, people also receive calcium channel blocker and diuretic (Barrett et al, personal communication) at combined cost of $2.04/day, plus
appropriate pharmacist prescribing fees.
‡‡Assumes 2.6%, 11.6%, and 39.4% of people with stage 3, 4, and non-dialysis stage 5 CKD are taking ESA,
68 and based on average dose of 3351
units/week
68 ($15.31/1000 units).
§§Assumes that 2.7% of all people with GFR <60 ml/min/1.73 m
2 are managed in multidisciplinary CKD clinic.
69
RESEARCH
page 6 of 12 BMJ | ONLINE FIRST | bmj.comIn subgroups of people with and without diabetes,
the cost per QALY gained was $22600 and $572000
, respectively. In a cohort of 100000 people with dia-
betes,screeningwouldbeexpectedtoreducethenum-
ber of people developing end stage renal disease over
theirlifetime from1796to 1741(fig 1). Inpeoplewith-
out diabetes with and without hypertension, the cost
per QALY gained was $C334000 and $C1411100,
respectively (table 6).
Sensitivity analyses
Tables 7, 8, and 9 show the results of sensitivity ana-
lyses conducted for the model overall, while tables 10
and 11 show the results of sensitivity analyses on the
effectiveness of angiotensin blockade in patients with
andwithoutdiabetes,respectively.Sensitivityanalyses
showed that screening restricted to people with dia-
betes was generally associated with a cost per QALY
gainedof <$25000, whichwas robustto changesin all
plausible variables (tables 7-10). Screening in people
without diabetes, however, was associated with a cost
per QALY of around $50000 only under scenarios
where identification of chronic kidney disease would
result in use of treatments that could improve survival
byatleast15%,andwhentheriskofprogressiontoend
stagerenaldiseaseintheabsenceoftreatmentwassub-
stantially higher than in the base case (table 11).
Probabilistic sensitivity analysis
Figures 2 and 3 show scatterplots of the incremental
cost effectiveness of population based screening com-
pared with no screening overall, highlighting uncer-
tainty in the analysis, which is largely attributed to
uncertaintyregardingtheimpact ofangiotensinblock-
ade on mortality in people without diabetes and with
chronic kidney disease. Given the current evidence of
benefitforangiotensinblockadeonbothmortalityand
end stage renal disease in people with diabetes and
chronic kidney disease, screening of people with dia-
betes led to better clinical outcomes in all simulations.
Our analysis indicates a 37% probability that targeted
screening for chronic kidney disease among people
with diabetes is associated with a cost per QALY
gained of <$20000 and a 99% probability that the
cost per QALY gained is <$50000.
DISCUSSION
Population based screening for chronic kidney disease
isunlikelytobecosteffectiveinunselectedpeopleorin
those without diabetes. Although the prevalence of
chronic kidney disease might be high enough to
make screening worthy of consideration, particularly
among older people,
10 most people who would be
found to have chronic kidney disease under a popula-
tion based screening strategy would not have diabetes
and would be likely to have non-proteinuric chronic
kidney disease, relatively slow loss of kidney function,
and low potential to benefit from angiotensin
blockade.
39 Therefore, the overall benefit of detecting
and treating asymptomatic chronic kidney disease
among people without diabetes is low. On the other
hand, in people with diabetes, rates of progression to
end stage renal disease are much higher, and there is
strong evidence that angiotensin blockade reduces
such progression
333642 and improves survival.
51
Given this, our study found that screening for chronic
kidney disease in people with diabetes is associated
with a cost per QALY in a range that is generally con-
sidered acceptable.
52-54
Strengths and limitations
We modelled progression of chronic kidney disease
and mortality stratified by age, diabetes, and presence
or absence of proteinuria using a large cohort of
patients with chronic kidney disease followed over
five years and estimated the benefit of screening from
high quality meta-analyses of angiotensin blockade.
Given that previous analyses examining the cost effec-
tiveness of screening have used urine based screening
methods,
1213andasthismightmissaconsiderablepro-
portion of people with chronic kidney disease,
10 we
used estimated glomerular filtration rate to screen for
Table 6 |Cost effectiveness of population based screening for
chronic kidney disease and for targeted screening of high
risk groups based on age, diabetes, and hypertension
Outcome
Incremental
cost ($C)
Incremental
QALYs
Cost ($C)
per QALY
Overall 463 0.0044 104 900
Age <65 148 0.0007 200 100
Age ≥65 997 0.0106 93 700
With diabetes 578 0.0256 22 600
Without diabetes 440 0.0008 572 000
Without diabetes
and hypertension
350 0.0003 1 411 100
Without diabetes
with hypertension
470 0.0014 334 000
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Fig 3 | Incremental cost effectiveness scatterplot of population based screening for chronic
kidney disease compared with no screening in people with diabetes
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ofouranalysisisthatwedidnotcompareourresultsto
a strategy of screening with urinalysis or a combined
strategy of glomerular filtration rate and urinalysis,
though all patients detected as having chronic kidney
disease were assumed to undergo urinalysis. Protei-
nuria is a powerful predictor of an increased risk of
end stage renal disease and death in people with
chronic kidney disease.
55 While screening with esti-
mated glomerular filtration rate might identify more
people than screening with urinalysis, most people
identified are at lower risk of adverse outcomes and
donotseemtogainadditionalbenefitfromangiotensin
blockade.
39
Our analysis was limited by the validity and avail-
abilityofrandomisedtrials(andmeta-analyses)report-
ingtheeffectivenessofmanagingpatientswithchronic
kidney disease. In general though, our analyses were
guided by estimates of effectiveness from high quality
meta-analyses. Screening in people without diabetes
was unattractive given that angiotensin blockade does
not seem to reduce mortality in people with non-dia-
betic renal disease.
3839 When we assumed that angio-
tensin blockade reduced mortality by 16% among
people without diabetes (consistent with results of a
large trial in which most participants did not have
chronic kidney disease
37), the cost per QALY for
screening people without diabetes became more
attractive ($40800), though it is unclear whether this
is a reasonable assumption. It could also be argued
that people who are identified as having chronic kid-
ney disease would be more likely to receive statins,
whichhavebeenprovedtoimprovesurvivalinpeople
with mild to moderate chronic kidney disease.
56-59 In
our analysis, however, we assumed that people at risk
of cardiovascular events would already be receiving
statins or aspirin (even without screening for chronic
kidney disease). We therefore modelled only the
impact of adding angiotensin blockade. In scenarios
where we modelled the impact of treating identified
patients with statins as well (resulting in a reduction in
mortalityof16%
58atanadditionalcostof$620ayear),
then the cost per QALY for screening in people with-
out diabetes was $53700.
We assumed that the incidence of end stage renal
disease and death, which was determined in a cohort
of people with known chronic kidney disease, would
be similar to a cohort of previously unidentified
patients with chronic kidney disease who were
detected through screening. Although this assumption
might overestimate, or underestimate, the true risks,
our results were robust to plausible changes in these
variables. We also assumed that people with chronic
kidney disease identified by screening would not be
receiving angiotensin blockade, which seems reason-
able given that they had not previously had their glo-
merular filtration rate measured. Of note, the results
did not vary significantly when up to 20% of patients
screenedwerealreadyreceivingangiotensinblockade.
Finally, our results are most relevant to the Canadian
setting. Given that our prevalence estimates are based
Table 8 |Sensitivity analysis of cost per QALY for screening
for chronic kidney disease (CKD) with varied incidence of
disease and rates of progression to end stage renal disease
(ESRD) in untreated patients
Outcome
Incremental Incremental
cost ($C) QALYs
Cost ($C)
per QALY
Baseline
Overall 463 0.0044 104 900
People with diabetes 578 0.0256 22 600
People without diabetes 440 0.0008 572 000
Incidence of CKD increased by 50% (baseline see table 4)
Overall 682 0.0066 103 000
People with diabetes 853 0.0384 22 200
People without diabetes 646 0.0012 547 400
Incidence of CKD decreased by 50% (baseline see table 4)
Overall 244 0.0022 110 300
People with diabetes 300 0.0128 23 500
People without diabetes 232 0.0004 603 300
Reduce risk of progression to ESRD by 50% (baseline see table 2)
Overall 521 0.0041 126 400
People with diabetes 682 0.0259 26 300
People without diabetes 495 0.0004 1 172 900
Reduce risk of progression to ESRD by 25% (baseline see table 2)
Overall 490 0.0043 114 500
People with diabetes 623 0.0257 24 183
People without diabetes 465 0.0006 771 100
Increase risk of progression to ESRD by 50% (baseline see table 2)
Overall 420 0.0046 90 400
People with diabetes 513 0.0252 20 351
People without diabetes 398 0.0011 376 500
Increase risk of progression to ESRD by 100% (baseline see table 2)
Overall 387 0.0048 80 200
People with diabetes 474 0.0249 19 100
People without diabetes 367 0.0013 282 200
Table 7 |Sensitivity analysis of cost per QALY of screening for chronic kidney disease with
varied rates of screening, use of angiotensin blockade, and adherence
Outcome Incremental cost ($C) Incremental QALYs Cost ($C) per QALY
Baseline
Overall 463 0.0044 104 900
People with diabetes 578 0.0256 22 600
People without diabetes 440 0.0008 572 000
Screening adherence rate increased to 100% (baseline 50%)
Overall 926 0.0088 104 900
People with diabetes 1153 0.0511 22 600
People without diabetes 880 0.0015 572 000
Adherence with angiotensin blockade increased to 100% (baseline 75%)
Overall 458 0.0059 77 800
People with diabetes 599 0.0341 16 400
People without diabetes 434 0.0010 423 100
20% of patients already receiving angiotensin blockade (baseline 0%)
Overall 487 0.0035 141 100
People with diabetes 621 0.020 31 100
People without diabetes 464 0.0006 761 100
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10 our esti-
matesofefficacybasedonrandomisedtrialsconducted
throughout the world, and that Canada has publicly
funded healthcare and relative costs that are likely
similar to Europe, we think that our results are likely
to be valid in other countries.
Comparison with other studies
Previousstudieshaveexaminedonlythecosteffective-
nessofscreeningwithurinalysisorurinebasedquanti-
tative proteinuria.
121360 Like our study, these studies
found that targeted screening of high risk groups (but
not population based screening) might be cost
effective.
1213 An analysis by Boulware et al suggested
that screening for chronic kidney disease with mea-
surement of proteinuria in patients with hypertension
was associated with a cost per QALY of less than US $
20000.
12 These analyses, however, assumed that
angiotensin blockade would improve survival in peo-
plewithoutdiabetes,
12anassumptionnotsupportedby
available data in patients with chronic kidney
disease.
3839 A study examining the cost effectiveness
of population based screening for urinary albumin
excretion, with treatment of those noted to have albu-
min excretion >15 mg/day with fosinopril to prevent
cardiovascular events, based on the PREVEND study
cohort,reportedacostperlifeyeargainedof€16700.
60
Population based screening for chronic kidney dis-
ease has been advocated by some,
41516 and the
National Kidney Foundation/Kidney Dialysis Out-
comes Quality Initiative clinical practice guidelines
forchronickidneydiseasehaverecommendedscreen-
ing for people at high risk of kidney disease, including
those with diabetes and hypertension and aged over
60.
114 Given that considerable resources would be
required to set up a population based screening pro-
gramme, our results are important. Our analyses sug-
gest that screening for chronic kidney disease with
estimatedglomerular filtration rateisnot costeffective
inolderpeopleorinthosewithoutdiabeteswithhyper-
tensionbutforpeoplewithdiabetesisassociatedwitha
cost per QALY gained in the range of other funded
interventions. We could not determine whether
screening with urinalysis might be more cost effective
overall or in certain subgroups compared with esti-
mated glomerular filtration rate.
Conclusions
Ourresultssuggestthatpopulationbasedscreeningfor
chronic kidney disease with assessment of estimated
glomerular filtration rate is not cost effective overall
or in subgroups of people without diabetes but with
hypertension or in elderly people. Targeted chronic
kidneydiseasescreeningwithestimatedglomerularfil-
tration rate in people with diabetes is associated with a
cost per QALY that is similar to other publicly funded
interventions.
Table 9 |Sensitivity analysis of cost per QALY for screening for chronic kidney disease (CKD),
exploring impact of variations in costs and quality of life
Outcome Incremental cost ($C) Incremental QALYs Cost ($C) per QALY
Baseline
Overall 463 0.0044 104 900
People with diabetes 578 0.0256 22 600
People without diabetes 440 0.0008 572 000
Costs for screening, CKD management, dialysis, and transplantation increased 50%
Overall 695 0.0044 157 000
People with diabetes 865 0.0256 33 800
People without diabetes 660 0.0008 857 900
Costs for screening, CKD management, dialysis, and transplantation decreased 50%
Overall 232 0.0044 52 400
People with diabetes 295 0.0256 11 500
People without diabetes 220 0.0008 286 000
Assuming newly diagnosed patients will have no additional cost for antihypertensive medications
Overall 177 0.0044 40 100
People with diabetes 175 0.0256 6900
People without diabetes 169 0.0008 219 800
Physician costs for screening (both GP visits) reduced to 0 (baseline $C35.26)*
Overall 445 0.0044 100 800
People with diabetes 558 0.0256 21 800
People without diabetes 422 0.0008 548 500
Only 20% of people with stage 3 disease referred to specialist (remaining 80% managed by GP)
Overall 416 0.0044 94 247
People with diabetes 514 0.0256 20 116
People without diabetes 395 0.0008 513 478
Annual cost of medication, physicians fees, and laboratory costs associated with managing patients with
diagnosis increased by 50%
Overall 745 0.0044 168 700
People with diabetes 975 0.0256 38 100
People without diabetes 706 0.0008 918 300
Annual cost of dialysis increased by 50% (baseline $C64 218)
Overall 420 0.0044 95 100
People with diabetes 501 0.0256 19 600
People without diabetes 399 0.0008 519 000
Annual cost of dialysis decreased by 50% (baseline $C64 218)
Overall 444 0.0044 100 500
People with diabetes 531 0.0256 20 800
People without diabetes 422 0.0008 548 600
High estimate utility value (0.90) associated with living with CKD (baseline 0.85)
Overall 463 0.0048 97 100
Diabetes 577 0.0273 21 200
Non-diabetes 440 0.0009 488 700
Low estimate utility value (0.75) associated with living with CKD (baseline 0.85)
Overall 463 0.0037 124 700
Diabetes 577 0.0222 26 000
Non-diabetes 440 0.00051 867 400
Discount rates decreased to 0%
71 (baseline 5%)
Overall 622 0.0087 71 800
People with diabetes 796 0.0536 14 800
People without diabetes 588 0.0011 520 200
Discount rates decreased to 3%
71 (baseline 5%)
Overall 515 0.0057 91 084
People with diabetes 645 0.0335 19 250
People without diabetes 489 0.0009 540 733
ESRD=end stage renal disease.
*Assumes that CKD screening would be done during annual visit and costs of screening would include only cost
of laboratory tests.
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